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Key Clinical Message
Insulinomas are uncommon tumors, and in patients with diabetes mellitus they
are extremely rare. We describe a patient with type 1 diabetes who developed
malignant insulinoma. When hypoglycemic episodes persist in a patient with
diabetes and treatment-induced and other causes of hypoglycemia have been
ruled out, an insulin-producing tumor should be considered.
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Introduction
Insulinomas are insulin-producing neuroendocrine neo-
plasms. They comprise the most common functional neu-
roendocrine tumor of the pancreas despite being rare, with
an estimated incidence of only 0.7–4 cases per 1 million per-
sons per year [1]. Most insulinomas occur sporadically, but
up to 10% are associated with the multiple endocrine neo-
plasia type 1 (MEN1) syndrome [2]. The tumor occurs at
any age with a median age at diagnosis of around 50 years,
and there is a slight female preponderance [2]. Approxi-
mately 5–10% of insulinomas are malignant [3]; these
tumors tend to be larger and have a higher mitotic count. A
diagnosis of malignancy is reached by identification of
metastatic disease, usually in lymph nodes or the liver.
Clinically, insulinomas are characterized by Whipple’s
triad [4], that is, the following three criteria: (1) presence
of central nervous system or vasomotor symptoms of
hypoglycemia; (2) low laboratory-measured concentration
of plasma glucose at the time of symptoms; and (3)
prompt resolution of symptoms when the plasma glucose
level returns to the normal range. The symptoms may be
provoked by a 72-h monitored fast. Upon confirmation
of hypoglycemia, further laboratory investigations are nec-
essary to establish its etiology. Inappropriately elevated
insulin levels (>3 mIU/L) at the time of hypoglycemia
(<2.5 mmol/L), together with elevated C-peptide
(>0.2 nmol/L) and proinsulin (≥25% or ≥22 pmol/L)
levels [5], and the absence of plasma sulfonylurea are
consistent with endogenous hyperinsulinism. When the
diagnosis is established, different pre- and/or intraopera-
tively imaging modalities are used to localize the insulin-
producing tumor, which typically is solitary, small, and
intrapancreatic [6, 7]. Surgical resection is the treatment
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of choice. When possible, enucleation or segmental resec-
tion is performed to preserve endocrine and exocrine
pancreatic function. The mean cure rate has been
reported to be 93% in a review of more than 6000 insuli-
noma cases [8]. The clinical course of metastatic insuli-
noma is variable, 25–35% of patients surviving longer
than 5 years [6].
The incidence of insulinoma in patients with diabetes is
considered to be lower than in the general population [9],
and reported cases have been almost exclusively in type 2
diabetes mellitus (T2DM). Furthermore, hypoglycemia
due to treatment with a hypoglycemic agent is not uncom-
mon among patients with diabetes, and the detection of
an insulinoma therefore represents a diagnostic challenge.
We describe the clinical history and management of a
malignant insulinoma diagnosed in a patient who had suf-
fered from type 1 diabetes mellitus (T1DM) for 20 years.
The patient has previously been included in summary
tables describing 16 insulinoma cases referred to Hauke-
land University Hospital between 1986 and 2006 [10].
Case Report
A 43-year-old woman was referred to our hospital with a
three-year history of decreasing insulin requirements and
frequent hypoglycemic episodes. Diabetes mellitus had
been diagnosed when the patient was 23 years old and, ini-
tially, she was treated by diet only. Islet antibodies and C-
peptide were not measured at the time of diagnosis. At age
24, after a weight loss of 14 kg accompanied by polydipsia
and polyuria, a diagnosis of T1DM was established and
insulin treatment started. The patient’s body mass index
(BMI) at that time was 17.6 (height 170 cm, weight 51 kg).
In the following years, her diabetes was well controlled, and
there were no microvascular complications. She was also
treated for hypothyroidism and hypertension from age 38.
The patient’s family history included a sister with pri-
mary hyperparathyroidism, another sister with breast can-
cer diagnosed at age 43, a father who had T2DM,
hypothyroidism and cardiovascular disease, a mother with
vitamin B12 deficiency, and a cousin with hypothyroidism
and celiac disease. The patient had two children, and her
son developed T1DM at the age of 20. No cases of MEN1
syndrome were known in the family.
The patient was treated with an insulin pump during
pregnancy when she was 31 years old. Otherwise her
insulin requirements were stable, requiring approximately
42–50 international units (IU) of insulin daily, given as
four bolus doses at mealtimes and one basal dose at bed-
time. However, at age 40, her total daily insulin require-
ment started to decrease and was recorded as 28 IU at
age 41 (Fig. 1). During the next year, intermediate-acting
(NPH) insulin was discontinued, and mealtime bolus
doses were gradually reduced to a total of 8 IU per day.
Despite these measures, the patient was experiencing fre-
quent and long-lasting hypoglycemic episodes, especially
during the night. She also had detectable insulin C-pep-
tide level at 0.7 nmol/L (normal range, NR: 0.17–
1.0 nmol/L). Chromogranin A was elevated at 6.6 nmol/L
(NR: 0.4–2.0). However, the patient had been taking
esomeprazole for abdominal discomfort, which may cause
increased chromogranin A.
On admission at age 43, the patient reported a weight
gain of 10 kg during the last 2 years, (current weight:
75 kg; BMI: 26.0). She looked fit and well. Her blood
pressure was 140/80 mm Hg. There was no abdominal
tenderness or palpable abdominal tumor. HbA1c was only
slightly elevated at 7.0% (NR: 4.0–6.4%). Insulin treat-
ment was discontinued, and the patient underwent a pro-
longed fast. After 24 h, she had symptoms of
hypoglycemia, a bedside glucometer showed a blood glu-
cose level of 1.9 mmol/L, and the fast was terminated.
Laboratory-measured plasma glucose was 2.8 mmol/L, C-
peptide was 0.58 nmol/L, and plasma insulin 3.8 mIU/L.
The concurrent plasma insulin and glucose values were
interpreted to be within normal limits, and therefore an
insulinoma was considered to be less likely. A diagnosis of
T2DM was also considered as the patient had been treated
with diet only for the first year after her diabetes diagno-
sis, C-peptide was measurable, and there was a family his-
tory of T2DM and cardiovascular disease. The patient was
discharged without insulin treatment and advised to
return to the hospital if hypoglycemia recurred.
Two months later, she was readmitted after a pro-
tracted hypoglycemic episode. Laboratory investigations
revealed elevated glutamic acid decarboxylase (GAD)
autoantibodies at 4 U/mL (NR: <1) and slightly elevated
plasma glucagon at 84 pmol/L (NR: 7.2–72). The values
for islet antigen-2 autoantibodies, hemoglobin, erythro-
cyte sedimentation rate, C-reactive protein, calcium,
parathyroid hormone, prolactin, gastrin, human chorionic
gonadotropin, alpha-fetoprotein, pancreas polypeptide,
adrenocorticotropic hormone, calcitonin, and liver tests
were all within normal ranges. A new fast was then per-
formed until hypoglycemia could be verified by the hospi-
tal laboratory. Sixteen hours after food intake, plasma
glucose was 2.5 mmol/L, C-peptide 0.56 nmol/L and
plasma insulin 9.7 mIU/L. Two hours later, plasma glu-
cose was 2.0 mmol/L, C-peptide 0.60 nmol/L, and plasma
insulin 8.2 mIU/L.
Endogenous hyperinsulinism was now considered to be
the cause of the patient’s hypoglycemia. Abdominal ultra-
sound examination showed a hypoechoic lesion with a
diameter of around 10 cm in the pancreatic tail. CT
examination (Fig. 2A) confirmed the presence of a large
retroperitoneal tumor and also revealed enlarged
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retroperitoneal lymph nodes as well as two possible liver
metastases. Octreotide scintigraphy demonstrated
increased uptake in the large tumor, but none in the liver
or other organs. The patient underwent surgery, and the
pancreatic lesion was removed. The surgical specimen
(Fig. 2B) consisted of the body and tail of the pancreas
with a well-circumscribed, large central tumor measuring
11 9 7 9 5.5 cm, the spleen, hilar and peripancreatic fat,
lymph nodes, and left adrenal. Also resected were two
liver metastases, each measuring 1 9 0.5 9 0.5 cm. The
tumor was partly demarcated by a thin pseudocapsule of
connective tissue and showed a light gray-yellowish cut
surface with a variegated, mainly soft consistency.
Histological examination (Fig. 3A–D) revealed an
epithelial tumor with varying histological growth pattern,
including nested, trabecular, gyriform, and solid areas.
There was a varying amount of fibrous stroma, focally
with a marked sclerotic quality. The tumor cells showed a
varying degree of slightly granular eosinophilic to ampho-
philic cytoplasm and moderately pleomorphic round to
oval nuclei with coarsely clumped chromatin and one or
more centrally placed distinct nucleoli. Mitoses were
nearly undetectable; <1 mitosis per 10 high-power fields
on average. There was no inflammatory response.
Routine immunohistochemistry (Fig. 3E–H) showed
diffuse and strong positivity for chromogranin A and
synaptophysin. Insulin expression was diffuse and moder-
ate, with smaller areas exhibiting strong positivity. Stain-
ing for somatostatin showed diffuse positivity with
varying intensity. A minority of the tumor cells exhibited
positivity for glucagon. Staining for vimentin, calcitonin,
gastrin, human growth hormone, ACTH, and thyroid
transcription factor was negative. Ki-67 proliferation
index was <1%. Two peripancreatic lymph node metas-
tases and two liver metastases showed the same morpho-
logical pattern and immunohistochemistry profile as the
primary tumor (Fig. 4), that is, diffuse and strong
immunoreactivity for chromogranin A and synapto-
physin, although only focal immunoreactivity for insulin.
The left adrenal was unremarkable.
Islets in the nontumorous pancreatic tissue of the
resection specimen (Fig. 5) consisted almost exclusively of
glucagon-positive cells. There was no positivity for insu-
lin. Neither the islets nor the exocrine parenchyma
showed significant infiltration of inflammatory cells.
Taken together, the clinical, morphological, and immuno-
histochemical findings were those of a malignant insuli-
noma.
Immediately after surgery, the plasma glucose concen-
tration increased, C-peptide became undetectable, and
chromogranin A fell to 0.8 nmol/L (Fig. 1). Insulin ther-
apy was reintroduced. The patient was discharged on a
Figure 1. Time line illustrating major events in the patient’s medical history, with age shown along the x-axis. Insulin requirements and serum
chromogranin A levels are indicated by open blue and solid red dots, respectively.
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basal/bolus regime of 34 IU insulin daily. Chromogranin
A and C-peptide were undetectable, and it was decided
not to give adjuvant treatment with a somatostatin analog
(octreotide) or other chemotherapy as all known tumor
tissue had been removed.
Five months after surgery, a CT examination revealed
two new liver metastases, while C-peptide and chromo-
granin A remained undetectable. Because the patient was
asymptomatic, further treatment was not initiated at this
point. Six months later, numerous liver and regional
lymph node metastases had emerged, giving rise to pleio-
tropic symptoms, mainly weight loss and night sweats,
but not those of hyperinsulinemia. Liver function tests
were normal, and C-peptide and chromogranin A were
undetectable. Due to multifocal metastatic disease, the
patient was not eligible for surgery and was treated pallia-
tively with 5-fluorouracil and streptozocin. Initially, there
was remarkable alleviation of symptoms, and the patient’s
performance status was close to normal. Follow-up CT
scans showed regression of the largest liver metastasis,
and there was no sign of disease progression for almost
2 years. She then developed icterus and a marked eleva-
tion of liver enzymes ascribed to chemotherapy-induced
hepatotoxicity. Streptozocin and 5-fluorouracil were
therefore discontinued.
Subsequently, liver enzymes normalized, but the size
and number of liver metastases increased. There was reoc-
currence of night sweats and slightly elevated chromo-
granin A (3.2 nmol/L). Hypoglycemic episodes were not
recorded. A biopsy from one of the liver metastases
showed strong immunoreactivity for synaptophysin and
chromogranin A, but none for insulin. Attempted treat-
ment with octreotide and interferon had to be terminated
because of hepatotoxicity.
Four and half years after the initial surgery, the patient
underwent whole-body [11C]5-hydroxytryptophan posi-
tron emission tomography at Uppsala University Hospi-
tal. There was uptake in the liver and in para-aortic
lymph nodes. Due to the risk of liver failure and the exis-
tence of extrahepatic disease, the patient was not consid-
ered to be a candidate for treatment with radioactive
lutetium or liver transplantation. During the following
months, further disease progression occurred with multi-
ple liver metastases and ascites, and the patient was trea-
ted with liver embolization (transarterial embolization
with microspheres) at Rikshospitalet, Oslo. In three sub-
sequent sessions over a 1.5-year period, a large part of the
right liver lobe and segments 2, 3, and 4 of the left lobe
were embolized. This procedure and spironolactone treat-
ment alleviated symptoms for a period of time.
Five years after the insulinoma diagnosis, at age 48, the
patient was diagnosed with lobular carcinoma of the right








Figure 2. (A) Preoperative computed tomography image at the level
of cauda pancreatis, portal venous contrast phase. A large tumor (T)
is seen in the pancreatic tail. (B) The surgical specimen consisting of
the pancreatic tail with a large, circumscribed tumor (T), the spleen
(S), and hilar and peripancreatic fat. An incision has been made in the
tumor to expose the inner surface. The asterisk indicates the resection
margin toward the residual pancreas. (C) Similar image as A, 11 years
after surgery. Two hypervascular liver metastases are evident (arrows).
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(5 and 11 mm) of a grade 2 lobular carcinoma were com-
pletely resected. Estrogen and progesteron receptors were
positive and HER2 negative. A sentinel node revealed one
micrometastasis. The patient was given postoperative
locoregional radiation therapy (2 Gy 9 25) and antiestro-
gen treatment with tamoxifen. Follow-up showed no
breast cancer recurrence.
Seven years after pancreatic surgery, and following sev-
eral months of stable disease, there was again progression
of the residual liver metastases, and chromogranin A
levels were rising. The patient was given second-line treat-
ment with temozolomide and capecitabine for nearly
2 years. During this time, she developed portal vein
thrombosis, which was treated with injections of low-
molecular-weight heparin. She did not have any
hypoglycemic episodes, and her diabetes was well regu-
lated with stable insulin requirements. She was then
observed for 1 year without treatment.
Ten years postsurgery, temozolomide and capecitabine
were reintroduced, but had to be discontinued due to
intractable side effects (diarrhea, abdominal pain, general
weakness). However, the patient’s diarrhea and abdominal
pain did not improve, and celiac disease was diagnosed
based on elevated tissue transglutaminase-immunoglobu-
lin A, positive HLA DQ2/DQ8 and typical findings in
duodenal biopsies. The abdominal symptoms improved
with a gluten-free diet. Abdominal CT showed slow pro-
gression of the liver metastases (Fig. 2C).
During this period, chromogranin A levels started to









Figure 3. (A–D) Hematoxylin/eosin histological images of the tumor illustrating its varying growth patterns. (A and B) Nested growth pattern with
various amounts of sclerotic stroma. (C) Solid diffuse growth pattern. (D) Trabecular pattern. (E–H) Immunohistological profile of the tumor tissue.
(E) Synaptophysin. (F) Glucagon. (G) Insulin. (H) Proliferation marker Ki-67. Scale bars: 200 lm (A, C, E, F, G); 75 lm (B, D, H).
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admitted to hospital with acute confusion and in poor
general condition. Octreotide scintigraphy showed, in
addition to multiple liver and lymph node metastases,
uptake in the peritoneum, suspicious for peritoneal carci-
nomatosis. A CT scan of the head did not reveal any
specific pathological findings. There were no hypo-
glycemic episodes. The patient died a few days later. A
postmortem examination was not permitted by the
relatives.
Discussion
In diabetes mellitus, hypoglycemic episodes are relatively
common and then usually associated with the use of
exogenous insulin or insulin secretagogues. The co-occur-
rence of diabetes and insulinoma poses diagnostic chal-
lenges and is sufficiently rare to deserve individual case
reports. In a series of 313 confirmed cases of insulinoma





Figure 4. Liver tissue with metastatic tumor deposits (right part of image) resected during the surgical removal of the primary tumor.





Figure 5. Nontumorous pancreatic tissue showing an islet of Langerhans (arrow) and a small pancreatic duct (arrowhead). Consecutive sections.
(A) Hematoxylin/eosin. (B) An islet highlighted by immunohistochemical staining for synaptophysin. (C) Glucagon. (D) No immunoreactivity for
insulin. Scale bars: 80 lm.
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one case of a functioning insulinoma in a patient with
established T2DM diagnosis [9]. In 1996, a review of the
literature retrieved 17 documented case reports of insuli-
nomas in patients with T2DM [11]. We have found only
two published case reports of insulinoma in patients with
a pre-existing diagnosis of T1DM [11, 12], although it
should be noted that tumor immunoreactivity to insulin
was documented in only one of the patients [12]. More-
over, two insulinoma patients have been diagnosed with
T1DM soon after surgical resection of the tumor, includ-
ing one case with documented insulitis and the absence
of beta cells in the nontumorous pancreatic tissue [13].
For the patient presented here, the evidence for an
autoimmune etiology of her diabetes is strong. A need for
insulin treatment within 1 year of diagnosis in a nonob-
ese young person is in itself suggestive of T1DM. More-
over, elevated GAD autoantibodies were detected, and
there was no sign of insulin expression in the islets of the
nontumorous pancreatic tissue removed during surgery.
C-peptide was undetectable postoperatively and insulin
requirement re-emerged immediately. Finally, the patient
had two other autoimmune disorders (hypothyroidism,
celiac disease) known to be associated with T1DM as well
as a son with this disease.
The histological appearance of the tumor together with
the immunoprofile (strong, diffuse positivity for chromo-
granin A and synaptophysin) confirmed the diagnosis of
a neuroendocrine tumor. The focal distribution of tumor
cells intensely positive for insulin together with clinical
and laboratory signs of insulin production is diagnostic
for an insulinoma [6]. The presence of liver metastases
and the course of the disease demonstrated the malig-
nancy of the tumor.
In retrospect, the insulinoma should have been diag-
nosed during the patient’s first hospital admission at age
43. The reason for the delayed diagnosis was partly a
belief that insulinoma and T1DM could not co-exist.
Moreover, the fast was stopped too early (after 24 h)
based on bedside blood glucose measurements that over-
estimated the degree of hypoglycemia. A prolonged fast
(up to 72 h) has a sensitivity approaching 100% for
detecting functioning insulinoma [14]. In addition, the
C-peptide level at the end of the first fast was not assessed
carefully enough. C-peptide measurement can exclude
exogenous insulin administration as cause of hyperin-
sulinism, and a concentration above 0.2 nmol/L in a
patient with hypoglycemia is suggestive of insulinoma [5,
14].
Given that the prevalence of diabetes mellitus is 5–10%
in industrial countries and that the incidence of insuli-
noma is 0.7–4 per 1,000,000 per year [1], co-existence of
the disorders should be more frequent than the literature
indicates. It is possible that the presence of diabetes
prevents the development of insulinoma or reduces the
clinical symptoms. In addition, hypoglycemia in diabetic
subjects is frequently observed and almost always caused
by overtreatment with glucose-lowering agents, making it
easy to neglect alternative explanations for persistent
hypoglycemia.
The demonstration of insulinoma in T1DM raises some
interesting questions with regard to the underlying patho-
physiology and origin of the tumor. The insulin-produ-
cing malignant cells must have been able to avoid the
autoimmune attack that otherwise had completely
destroyed the beta cells of the patient. Notably, there was
no evidence of an inflammatory response, neither in the
resected tumor nor in the normal pancreatic tissue.
Whether there was a lack of autoantigen expression in the
insulinoma cells or they were able to escape immune
surveillance in other ways will remain an open question.
In this regard, it should be noted that although the large
majority of insulinomas are benign [3, 8], the insulino-
mas of both the current and the two previously published
T1DM patients were malignant [11, 12].
In some cases, such as in the MEN syndrome and in
autoimmune chronic gastritis, neuroendocrine tumors
may develop in the context of endocrine cell hyperplasia
[15]. In long-standing T1DM, the pancreas has been
depleted of normal beta cells (Fig. 5D). It is therefore dif-
ficult to envisage that the insulinoma of the present case
developed from hyperplastic or normal beta cells. Instead,
we propose that that the pluripotency of uncommitted
stem cells is required to give rise to an insulin-producing
tumor in a patient who lacks normally functioning beta
cells and where such cells are likely to be constantly
attacked by the immune system.
Conclusion
This case report and previous publications show that
insulinoma can occur in individuals with diabetes, even
in patients with long-standing T1DM. Thus, when hypo-
glycemic episodes persist in a diabetic subject despite
reduction or discontinuation of hypoglycemic treatment,
and other causes of low blood glucose level have been
ruled out, the presence of an insulin-producing tumor
should be considered.
Acknowledgments
The authors are grateful to prof. Ingfrid S. Haldorsen,
Department of Radiology, Haukeland University Hospital,
Bergen, Norway, for discussion of the radiological images,
to staff members who cared for the patient at Haukeland
University Hospital, and to Helge K. Gjelberg for assis-
tance with Figure 1.
ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 767
H. K. Gjelberg et al. Malignant insulinoma in a type 1 diabetic patient
Authorship
HKG: evaluated the patient’s medical records, did the lit-
erature review, wrote the article draft, and made the fig-
ures. DH: operated the patient, provided the patient’s
consent, and contributed to the writing process. CSV: fol-
lowed up on all pathology data and made critical revi-
sions of the text and figures. JE: did the primary
pathology evaluation of the surgical specimen and con-
tributed to the writing process. JGC: performed the clini-
cal evaluation of the patient and contributed to the
writing process. AM: coordinated and supervised the writ-
ing process, performed critical revisions of the text and
figures, and is the corresponding author. All authors
approved the final manuscript version.
Consent for Publication
Informed and written consent were obtained from the
patient.
Conflict of Interest
The authors have no conflict of interests to disclose.
References
1. Halfdanarson, T. R., J. Rubin, M. B. Farnell, C. S. Grant,
and G. M. Petersen. 2008. Pancreatic endocrine neoplasms:
epidemiology and prognosis of pancreatic endocrine
tumors. Endocr. Relat. Cancer 15:409–427.
2. Service, F. J., M. M. McMahon, P. C. O’Brien, and D. J.
Ballard. 1991. Functioning insulinoma–incidence,
recurrence, and long-term survival of patients: a 60-year
study. Mayo Clin. Proc. 66:711–719.
3. Krampitz, G. W., and J. A. Norton. 2013. Pancreatic
neuroendocrine tumors. Curr. Probl. Surg. 50:509–545.
4. Whipple, A. O., and V. K. Frantz. 1935. Adenoma of islet
cells with hyperinsulinism: a review. Ann. Surg.
101:1299–1335.
5. Vezzosi, D., A. Bennet, J. Fauvel, and P. Caron. 2007.
Insulin, C-peptide and proinsulin for the biochemical
diagnosis of hypoglycaemia related to endogenous
hyperinsulinism. Eur. J. Endocrinol. 157:75–83.
6. Mathur, A., P. Gorden, and S. K. Libutti. 2009.
Insulinoma. Surg. Clin. North Am. 89:1105–1121.
7. Tucker, O. N., P. L. Crotty, and K. C. Conlon. 2006. The
management of insulinoma. Br. J. Surg. 93:264–275.
8. Mehrabi, A., L. Fischer, M. Hafezi, A. Dirlewanger, L.
Grenacher, M. K. Diener, et al. 2014. A systematic review
of localization, surgical treatment options, and outcome of
insulinoma. Pancreas 43:675–686.
9. Kane, L. A., C. S. Grant, T. B. Nippoldt, and F. J. Service.
1993. Insulinoma in a patient with NIDDM. Diabetes Care
16:1298–1300.
10. Hoem, D., D. Jensen, S. Steine, T. E. Thorsen, A. Viste,
and A. Molven. 2008. Clinicopathological characteristics
and non-adhesive organ culture of insulinomas. Scand. J.
Surg. 97:42–49.
11. Svartberg, J., M. Stridsberg, E. Wilander, D. E. Andersson,
and B. Eriksson. 1996. Tumour-induced hypoglycaemia in
a patient with insulin-dependent diabetes mellitus. J.
Intern. Med. 239:181–185.
12. Lablanche, S., M. Chobert-Bakouline, O. Risse, M. H.
Laverriere, O. Chabre, and P. Y. Benhamou. 2015.
Malignant insulinoma may arise during the course of type 1
diabetes mellitus: a case report. Diabetes Metab. 41:258–261.
13. Oikawa, Y., T. Katsuki, M. Kawasaki, A. Hashiguchi, K.
Mukai, K. Handa, et al. 2012. Insulinoma may mask the
existence of Type 1 diabetes. Diabet. Med. 29:e138–e141.
14. Service, F. J. 1995. Hypoglycemic disorders. N. Engl. J.
Med. 332:1144–1152.
15. Mete, O., and S. L. Asa. 2013. Precursor lesions of
endocrine system neoplasms. Pathology 45:316–330.
768 ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Malignant insulinoma in a type 1 diabetic patient H. K. Gjelberg et al.
